Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus

Hepatology

Volumn 61, Issue 1, 2015, Pages 41-45

  Yoshida, Eric M ^a   Sulkowski, Mark S ^b   Gane, Edward J ^c   Herring, Robert W ^d   Ratziu, Vlad ^e   Ding, Xiao ^f   Wang, Jing ^f   Chuang, Shu Min ^f   Ma, Julie ^f   Mcnally, John ^f   Stamm, Luisa M ^f   Brainard, Diana M ^f   Symonds, William T ^f   Mchutchison, John G ^f   Beavers, Kimberly L ^g   Jacobson, Ira M ^h   Reddy, K Rajender ⁱ   Lawitz, Eric ^j  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c New Zealand Liver Transplant Unit   (New Zealand)

^d PLLC   (United States)

^e SORBONNE UNIVERSITÉ   (France)

^f GILEAD SCIENCES   (United States)

^g Asheville Gastroenterology Associates   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; 2-((5-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER; ANTIVIRUS AGENT; URIDINE PHOSPHATE; VIRUS RNA;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RECURRENT DISEASE; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; RNA, VIRAL; URIDINE MONOPHOSPHATE;

EID: 84920939338     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27366     Document Type: Article

References (10)

1. Dieperink E, Pocha C, Thuras P, Knott A, Colton S, Ho SB. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci 2014;59:872-880.
2. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
3. Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-1455.
4. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al.; VALENCE investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
5. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
6. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
7. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2013.
8. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804-811.
9. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009:49:1335-1374.
10. Cheng W, Shafran S, Beavers K, Mo H, McNally J, Brainard DM, et al. Long term follow-up of patients treated with sofosbuvir in the FISSION, POSITRON, FUSION and NEUTRINO phase 3 studies. J Hepatol 2014;60(Suppl):S449.